Advertisement
Table 1 Key baseline patient demographics and characteristics
| Characteristic | Overall (N = 130)a | Patients with best response of SD (n = 32) |
|---|---|---|
| Age, median (range), y | 61 (20–83) | 61.5 (24–79) |
| ECOG performance statusb | ||
| 0 | 46 (35) | 10 (31) |
| 1 | 66 (51) | 17 (53) |
| 2 | 17 (13) | 5 (16) |
| International Prognostic Index, n (%) | ||
| <2 | 31 (24) | 7 (22) |
| ≥2 | 99 (76) | 25 (78) |
| PTCL subtype based on central review, n (%) | ||
| PTCL-NOS | 69 (53) | 16 (50) |
| AITL | 27 (21) | 8 (25) |
| ALK-1-negative ALCL | 21 (16) | 5 (16) |
| Other | 13 (10)c | 3 (9)d |
| Stage III/IV at diagnosis, n (%) | 91 (70) | 20 (63) |
| Number of prior therapies, n (%) | ||
| 1 | 38 (29) | 13 (41) |
| 2 | 44 (34) | 11 (34) |
| 3 | 19 (15) | 3 (9) |
| 4 | 15 (12) | 4 (13) |
| >4 | 14 (11) | 1 (3) |
| Type of prior therapy, n (%) | ||
| Chemotherapy | 129 (99) | 31 (97) |
| Monoclonal antibody therapy | 20 (15) | 3 (9) |
| Other immunotherapy | 14 (11) | 1 (3) |
| Radiation | 31 (24) | 8 (25) |
| ASCT | 21 (16) | 3 (9) |
| Refractory to most recent therapy, n (%) | 49 (38) | 8 (25) |
